Pharmaceutical Product Lost Profits
This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
Background
Two generic drug companies participated in an “at-risk” launch of generic versions of a multi-billion dollar gastroesophageal reflux drug. The generic drug companies launched “at-risk” by selling product after receiving FDA marketing approval, but while claims of patent infringement were still pending. A previous jury found that the patent-in-suit was valid and infringed, making economic damages the central remaining issue in the case.
Our Analysis
Intensity calculated the profits that the branded drug company lost as a result of sales of generic versions of the branded drug. As part of its lost profits analysis, Intensity performed a reconstruction of a “but-for world” in which the infringement never occurred.
Reconstruction of the but-for world became an economic issue in the case due to the timing and complexity of marketplace events. The first generic company launched its product in large quantities, but stopped selling just days later. The second generic company waited to launch its generic product until the day after the branded company launched its own generic product. The first generic resumed sales of its product a number of months later. Intensity performed an analysis to quantify the economic effects of these marketplace events on lost sales and lost profits.
Our work involved quantification of the unit sales and prices that the branded company would have realized in the but-for world. The analysis included a determination of unit sales that were lost as a result of generic entry as well as additional unit sales that were made as result of the generic entry. Similarly, we performed an analysis of price erosion to determine the prices that the branded drug would have been sold at if competing generic versions had not been sold. We specifically examined the factors influencing price differences that occurred upon generic entry.
This project also involved an analysis of the economic impact of corporate structure and transfer pricing on lost profits.
Latest Insights
Article | August 11, 2025
Five Key Recommendations to Strengthen Cybersecurity in Latin America and the Caribbean
Cybersecurity is now a core element of legal, regulatory, and business risk management. In Latin America and the Caribbean, organizations face mounting pressure to demonstrate proactive compliance with evolving data protection laws, cybersecurity mandates, and cross-border disclosure requirements. Boards and legal departments are expected not only to prevent cyber incidents but also to prove due diligence, resilience planning, and rapid response capabilities when they occur.
News | July 28, 2025
Expert Economic Testimony Plays Crucial Role in Puerto Rico Healthcare Antitrust Case
Director Jason Albert provided pivotal testimony in Roberto Vázquez-Ramos, et al. v. Triple-S Salud, et al., which examined allegations of unfair competition and monopolistic practices involving exclusive provider arrangements under Puerto Rico’s government health plan. In May 2019, the Plaintiffs—a group of urologists in Puerto Rico’s Western Region—alleged that Triple-S Salud (“Triple-S”), the region’s government […]
See All Insights
Talk to Our Insightful Experts